-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CWG-940 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CWG-940 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CWG-940 in Rheumatoid Arthritis Drug Details: CWG-940 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MPN-1 in Myeloproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MPN-1 in Myeloproliferative Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MPN-1 in Myeloproliferative Disorders Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARQ-154 in Plaque Psoriasis (Psoriasis Vulgaris)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ARQ-154 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: Roflumilast (Zoryve) is a long-acting selective phosphodiesterase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Debio-4126 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Debio-4126 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Debio-4126 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details:Debio-4126 is under development...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MPN-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MPN-1 Drug Details Small molecule is under development for the treatment of myeloproliferative neoplasms...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GBM-2
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GBM-2 Drug Details Small molecule is under development for the treatment of glioblastoma multiforme....
-
Product Insights
Rheumatoid Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to the destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue and fever, and weight loss. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications, and immunosuppressants. The Rheumatoid Arthritis Drugs in Development market research report provides an overview of the Rheumatoid Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage...